Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
Date:9/9/2008

quarter. The increase was primarily related to Peregrine's increased investment in research and development associated with the advancement of its three clinical programs for bavituximab and Cotara(R) for the treatment of solid tumors and hepatitis C virus (HCV) infection. Research and development expenses were $4,068,000 in the first quarter of FY 2009, compared to $3,624,000 in the first quarter of FY 2008. At July 31, 2008, the company had $9,963,000 in cash and cash equivalents compared to $15,130,000 at fiscal year end April 30, 2008. In addition, liquid assets, representing cash and receivables, were $13,856,000 at July 31, 2008 as compared with $15,735,000 at fiscal year end April 30, 2008.

"Among the most significant developments this past quarter was having patient enrollment underway in all three of the Phase II trials in our bavituximab cancer program and reporting encouraging positive data from the trial testing bavituximab in combination with docetaxel in advanced breast cancer patients," said Steven W. King, president and CEO of Peregrine. "The positive data from this trial showed that we had exceeded our pre-determined criteria for proceeding to the next stage of the trial, with half of patients demonstrating partial tumor responses. We are reporting today that we have now seen additional patients with tumor responses in this trial, with nine of the 14 evaluable patients having achieved a partial tumor response. During the quarter, we also reported data from a prior bavituximab cancer study and from our ongoing Cotara study in glioblastoma (GBM) patients at the prestigious ASCO meeting, building a promising foundation for future peer-reviewed presentations and publications from our clinical programs."

Mr. King continued, "Our bavituximab anti-viral program received a major validation during the quarter when we were awarded up to a five-year contract potentially worth up to $44.4 million with the DTRA to evaluate bavituximab for the treat
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
2. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
3. Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
4. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
5. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
6. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
7. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
8. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
9. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
10. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... (PRWEB) May 16, 2013 A ... portable models, from Cole-Parmer is designed to meet ... line includes: , The new Cole-Parmer® MS-3400 ... workhorses in the lab. They ensure a powerful ... plasma specimen separation. Their standard four-place swinging buckets ...
(Date:5/16/2013)... 2013  The registration deadline has been extended until ... 2013 National Conference, the premier conference for bioscience financial ... the Hilton San Diego Bayfront. "We ... and want to make sure as many people as ... Brandi Roberts , Chief Financial Officer of Mast ...
(Date:5/16/2013)... NEW YORK , May 16, ... a new market research report is ...   Competitor Analysis: ... Biosuperiors http://www.reportlinker.com/p01171947/Competitor-Analysis-Therapeutic-Proteins-–-Biosimilars-Biobetters--Biosuperiors.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical ...   The ...
(Date:5/16/2013)... Dr. Stephen Y. Chou, Founder of Nanonex Corporation, ... Applications” at IEEE Nano 2013 in Beijing, China, on ... Chou, is becoming one of the most critical nanofabrication ... nm resolution, large area, and low cost unmatchable by ... manufacturing in a broad range of industries, from ICs, ...
Breaking Biology Technology:Cole-Parmer Offers Enhanced Selection of Centrifuges 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 2Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 3Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 4Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 5Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 6Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 7Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors 8Founder, Prof. Stephen Chou to Give Tutorial on Nanoimprint at IEEE Nano 2013 2
... (NASDAQ: SQNM ), a life sciences company ... new publication from the large Women & Infants multi-center ... (Sequenom CMM) MaterniT21 PLUS laboratory-developed test (LDT) ... Prenatal Diagnosis . Along with this week,s publication, the ...
... May 16, 2012  Sigma-Aldrich announced today that it has ... will mature on May 10, 2017.  The new facility ... scheduled to mature on December 11, 2012.  The $600 ... paper program and be used for general corporate purposes. ...
... Reportlinker.com announces that a new market research ...   Global Anti-Microbial Coatings ...   This report analyzes the US ... the following End-Use Segments: Indoor Air Quality, and ...
Cached Biology Technology:Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets 2Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets 3Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets 4Study In Prenatal Diagnosis Finds Sequenom CMM's MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets 5Global Anti-Microbial Coatings Industry 2Global Anti-Microbial Coatings Industry 3Global Anti-Microbial Coatings Industry 4Global Anti-Microbial Coatings Industry 5Global Anti-Microbial Coatings Industry 6Global Anti-Microbial Coatings Industry 7Global Anti-Microbial Coatings Industry 8Global Anti-Microbial Coatings Industry 9Global Anti-Microbial Coatings Industry 10Global Anti-Microbial Coatings Industry 11Global Anti-Microbial Coatings Industry 12Global Anti-Microbial Coatings Industry 13
(Date:5/16/2013)... (GWA), where the entirety of an individual,s DNA is ... which can cause health problems is a massively useful ... pose major ethical problems if used incorrectly, say new ... published on line today (16 May 2013) in the ... based on whole genome and on exome* sequencing and ...
(Date:5/16/2013)... May 16, 2013 Reportlinker.com announces ... available in its catalogue: ... 2018 http://www.reportlinker.com/p01181929/Global-Biometric-Systems-Market-Forecast--Opportunities-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems ... security practises such as photographs, passwords and ... biometric technologies in last few years. Security ...
(Date:5/15/2013)... clinical trial to date to examine the efficacy of ... other than breast and ovarian cancer, the oral drug ... and prostate cancers. Results of the study, led by ... University of Pennsylvania and Sheba Medical Center in Tel ... of Clinical Oncology,s annual meeting in Chicago in early ...
Breaking Biology News(10 mins):European Society of Human Genetics urges caution over use of new genetic sequencing techniques 2Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations 2
... An anticipated increased incidence of climate-related extreme rainfall events ... risk for the 40 million people who depend on the ... In a report published today (Oct. 7, 2008) in ... of Wisconsin researchers reports that a trend toward extreme weather ...
... pulses inside us all, guiding our daily cycle from ... be doing much more than just that simple metronomic ... hamsters, biologist Norman Ruby has shown that having a ... to remember what they have learned. Without it, he ...
... , The cause of diseases such as BSE in ... This protein attaches to cell membranes by way of an ... anchor. The anchoring of the prions seems to have a ... the protein into its pathogenic form, which causes scrapie and ...
Cached Biology News:Waterborne disease risk upped in Great Lakes 2Waterborne disease risk upped in Great Lakes 3Circadian clock may be critical for remembering what you learn, Stanford researchers say 2Circadian clock may be critical for remembering what you learn, Stanford researchers say 3Circadian clock may be critical for remembering what you learn, Stanford researchers say 4Tracking down the cause of mad cow disease 2